Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Blood (2018) 132 (Supplement 1): LBA-1.

https://doi.org/10.1182/blood-2018-120738

Published: 2018

Journal Articles

Sustained Improvements in Fatigue and Quality of Life in Iron Deficiency Anemia Patients Following a Single Course of Ferumoxytol: Results of a 6-Month Extension Study

Saroj Vadhan-Raj, MD, Naomi V Dahl, PharmD, John Jiang, PhD, William E Strauss, MD

Blood (2018) 132 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2018-99-115511

Published: 2018

Journal Articles

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Saroj Vadhan-Raj, MD, Rafat Abonour, Jonathan W. Goldman, MD, David A. Smith, MD, Christopher A. Slapak, MD, Ramon V. Tiu, MD, Xuejing Wang, Sophie Callies, Joanne Cox, Jay L. Tuttle, PhD, Yiu-Keung (James) Lau, MD PhD, Eric J. Roeland, MD

Blood (2015) 126 (23): 537.

https://doi.org/10.1182/blood.V126.23.537.537

Published: 2015

Journal Articles

Effects of the Timing of Venous Thromboembolic Events on Survival of Patients with Uterine Cancer

Heera Remasankar, MD, Xiao Zhou, MD PhD, Saroj Vadhan-Raj, MD

Blood (2014) 124 (21): 1534.

https://doi.org/10.1182/blood.V124.21.1534.1534

Published: 2014

Journal Articles

Efficacy and Safety of IV Ferumoxytol (FER) for Iron Deficiency Anemia (IDA) in Patients with Cancer

Saroj Vadhan-Raj, MD, Naomi V. Dahl, Pharm D, Kristine Bernard, MPH, Zhu Li, PhD, William Strauss, MD, F.A.C.C.

Blood (2014) 124 (21): 1352.

https://doi.org/10.1182/blood.V124.21.1352.1352

Published: 2014

Journal Articles

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Saroj Vadhan-Raj, MD, Naomi V Dahl, Pharm.D., Gloria Lau, MSc, Kristine Bernard, Zhu Li, PhD, Pallabi De, PhD, Lee F. Allen, MD, PhD, William Strauss, M.D., F.A.C.C.

Blood (2013) 122 (21): 2201.

https://doi.org/10.1182/blood.V122.21.2201.2201

Published: 2013

Journal Articles

Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE

Saroj Vadhan-Raj, MD, Xiao Zhou, MD, PhD, Gauri R. Varadhachary, MD, MBBS, Javle Milind, MD, David Fogelman, MD, Rachna Shroff, MD, Carlos E. Bueso-Ramos, MD, PhD, Martin Nguyen, BS, Xuemei Wang, MS, Robert A. Wolff, MD, James L. Abbruzzese, MD, Michael J. Overman, MD

Blood (2013) 122 (21): 580.

https://doi.org/10.1182/blood.V122.21.580.580

Published: 2013

Journal Articles

Effects of the Timing and the Type of Venous Thromboembolic Events On Survival in Patients with Pancreatic Cancer

Vivek Kesari, MD, Maithili Shethia, MD, Xiao Zhou, MD, PHD, Michael Overman, MD, Saroj Vadhan-Raj, MD

Blood (2012) 120 (21): 1151.

https://doi.org/10.1182/blood.V120.21.1151.1151

Published: 2012

Journal Articles

Ferumoxytol Treatment Demonstrates Significant Improvements in Fatigue and Health-Related Quality of Life in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy

Saroj Vadhan Raj, Andrew Hsieh, William Strauss, M.D., F.A.C.C., Michael Stevenson, R.Ph., Ph.D., Kristine Bernard, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 478.

https://doi.org/10.1182/blood.V120.21.478.478

Published: 2012

Journal Articles

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Jatin J. Shah, M.D., Aparna Hegde, MD, Xiao Zhou, MD, PHD, Sheeba K. Thomas, MD, Michael Wang, MD, Donna M. Weber, M.D., Raymond Alexanian, MD, Robert Z. Orlowski, MD, PhD, Saroj Vadhan-Raj, MD

Blood (2012) 120 (21): 2244.

https://doi.org/10.1182/blood.V120.21.2244.2244

Published: 2012

Journal Articles

Interleukin-6, Hepcidin, and Other Biomarkers in Anemia of Chronic Disease (ACD) and Chemotherapy-Induced Anemia (CIA): Potential Therapeutic Targets.

Saroj Vadhan-Raj, MD, Xiao Zhou, MD, PHD, Carlos E. Bueso-Ramos, MD, PhD, Shreyaskumar Patel, MD, Robert S Benjamin, MD, Martin Ngyuen

Blood (2012) 120 (21): 2086.

https://doi.org/10.1182/blood.V120.21.2086.2086

Published: 2012

Journal Articles

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Saroj Vadhan Raj, Michael Cressman, David Ford, William Strauss, M.D., F.A.C.C., Gerri Poss, Kristine Bernard, Zhu Li, PhD, Lee F. Allen, MD, PhD

Blood (2012) 120 (21): 2098.

https://doi.org/10.1182/blood.V120.21.2098.2098

Published: 2012

Journal Articles

Venous Thromboembolism (VTE) in Patients with Hematologic and Non-Hematologic Malignancies: Incidence and Risk Factors for Recurrent VTE

Saroj Vadhan-Raj, MD, Xiao Zhou, MD, PHD, Jatin J Shah, MD, Robert S Benjamin, MD, Gregory Gladish, MD

Blood (2011) 118 (21): 2303.

https://doi.org/10.1182/blood.V118.21.2303.2303

Published: 2011

Journal Articles

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Saroj Vadhan-Raj, MD, Ivan Spasojevic, Ph.D., Xiao Zhou, MD, PHD, Jorge E Romaguera, MD, Michelle A. Fanale, MD, Luis E Fayad, MD, Nathan H. Fowler, MD, Auris Huen, PHARMD, F.B. Hagemeister, MD, Maria Alma Rodriguez, MD, Sattva S. Neelapu, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry W Kwak, MD, PhD

Blood (2011) 118 (21): 1613.

https://doi.org/10.1182/blood.V118.21.1613.1613

Published: 2011

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

Impact of Safety Concerns of Erythropoiesis-Stimulating Agents (ESAs) and Regulatory Changes on the Use of ESAs and Red Blood Cell (RBC) Transfusions at a Comprehensive Cancer Center

Saroj Vadhan-Raj, UTMD, Victoria E. Hawkins, MPH, DRPH, RN, Xiao Zhou, MD, PHD, Kurt Sizer, MD, Lincy S. Lal, PHD, PHARMD, RPH, Joyce Roquemore, MBA, CPHQ, Rebecca B. Arbuckle, MS, RPH, Robert S. Benjamin, MD, BA, Benjamin Lichtiger, MD, PhD

Blood (2008) 112 (11): 1300.

https://doi.org/10.1182/blood.V112.11.1300.1300

Published: 2008

Journal Articles

An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed (R) or Plateau-Phase (PP) Multiple Myeloma (MM).

Ravi Vij, Noemi Horvath, Andrew Spencer, Kerry Taylor, Saroj Vadhan-Raj, Judy Smith, Yi Qian, Susie Jun

Blood (2007) 110 (11): 3604.

https://doi.org/10.1182/blood.V110.11.3604.3604

Published: 2007

Journal Articles

Characteristics of Patients Experiencing Thromboembolic Events during Treatment for Multiple Myeloma: Aspirin May Not Be Adequate Thromboprophylaxis in Patients with Multiple Risk Factors.

Jennifer A. Wright, MD, Donna Weber, MD, Sheeba K. Thomas, MD, Michael Wang, MD, Raymond Alexanian, MD, Victoria E. Hawkins, DRPH, Saroj Vadhan-Raj, MD

Blood (2007) 110 (11): 1882.

https://doi.org/10.1182/blood.V110.11.1882.1882

Published: 2007

Journal Articles

Curcumin Downregulates NF-kB and Related Genes in Patients with Multiple Myeloma: Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Donna M. Weber, MD, BS, Michael Wang, MD, MS, Sergio A. Giralt, MD, Sheeba K. Thomas, MD, Raymond Alexanian, MD, Xiao Zhou, MD, Priya Patel, BS, Carlos E. Bueso-Ramos, MD, PHD, Robert A. Newman, PHD, MS, Bharat B. Aggarwal, PHD, MS

Blood (2007) 110 (11): 1177.

https://doi.org/10.1182/blood.V110.11.1177.1177

Published: 2007

NARROW

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

Sustained Improvements in Fatigue and Quality of Life in Iron Deficiency Anemia Patients Following a Single Course of Ferumoxytol: Results of a 6-Month Extension Study

Phase 1 Study of a Hepcidin Antagonist, LY2787106, in Cancer-Associated Anemia

Effects of the Timing of Venous Thromboembolic Events on Survival of Patients with Uterine Cancer

Efficacy and Safety of IV Ferumoxytol (FER) for Iron Deficiency Anemia (IDA) in Patients with Cancer

Safety and Efficacy Of Ferumoxytol For The Episodic Treatment Of Iron Deficiency Anemia In Patients With a History Of Unsatisfactory Oral Iron Therapy: Results Of a Phase III Open-Label, Six Month Extension Study

Randomized Controlled Trial Of Dalteparin For Primary Thromboprophylaxis For Venous Thromboembolism (VTE) In Patients With Advanced Pancreatic Cancer (APC): Risk Factors Predictive Of VTE

Effects of the Timing and the Type of Venous Thromboembolic Events On Survival in Patients with Pancreatic Cancer

Ferumoxytol Treatment Demonstrates Significant Improvements in Fatigue and Health-Related Quality of Life in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy

Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.

Interleukin-6, Hepcidin, and Other Biomarkers in Anemia of Chronic Disease (ACD) and Chemotherapy-Induced Anemia (CIA): Potential Therapeutic Targets.

Ferumoxytol Treatment Results in Robust Hemoglobin Increases in Iron Deficiency Anemia Patients with a History of Unsatisfactory Oral Iron Therapy in a Phase III, Randomized, Placebo-Controlled Trial.

Venous Thromboembolism (VTE) in Patients with Hematologic and Non-Hematologic Malignancies: Incidence and Risk Factors for Recurrent VTE

Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Impact of Safety Concerns of Erythropoiesis-Stimulating Agents (ESAs) and Regulatory Changes on the Use of ESAs and Red Blood Cell (RBC) Transfusions at a Comprehensive Cancer Center

An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed (R) or Plateau-Phase (PP) Multiple Myeloma (MM).

Characteristics of Patients Experiencing Thromboembolic Events during Treatment for Multiple Myeloma: Aspirin May Not Be Adequate Thromboprophylaxis in Patients with Multiple Risk Factors.

Curcumin Downregulates NF-kB and Related Genes in Patients with Multiple Myeloma: Results of a Phase I/II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only